[Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report)--a randomized controlled study]. 1985

H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao

We reported previously that Schizophyllan (SPG) combined with MMC + 5-FU (MF regimen) or Tegafur (F regimen) had a significant life-prolonging effect over chemotherapeutic regimens in patients with inoperable and recurrent gastric cancer in a randomized controlled study. In the present paper, we have further investigated the effect of SPG on life-span followed-up for more than 2 years. A significant life-prolonging effect of SPG was reconfirmed in patients given either the MF regimen (154 patients) or the F regimen (213 patients). Thus, SPG combined with chemotherapeutics has proved to be useful for treating patients with inoperable and recurrent gastric cancer, resulting in a significant prolongation of life-span without serious side effects despite having no influence on tumor size.

UI MeSH Term Description Entries
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006025 Glycosaminoglycans Heteropolysaccharides which contain an N-acetylated hexosamine in a characteristic repeating disaccharide unit. The repeating structure of each disaccharide involves alternate 1,4- and 1,3-linkages consisting of either N-acetylglucosamine (see ACETYLGLUCOSAMINE) or N-acetylgalactosamine (see ACETYLGALACTOSAMINE). Glycosaminoglycan,Mucopolysaccharides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012566 Sizofiran A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Schizophyllan,Sizofilan,Sonifilan

Related Publications

H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
September 1989, Nihon Geka Gakkai zasshi,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
April 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
July 1984, The Japanese journal of surgery,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
August 1986, Cancer,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
July 1985, Nihon Gan Chiryo Gakkai shi,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
February 1992, Japanese journal of clinical oncology,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
June 1977, Kekkaku : [Tuberculosis],
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
August 1994, Cancer letters,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
July 1980, Nihon Sanka Fujinka Gakkai zasshi,
H Furue, and H Uchino, and K Orita, and T Kimura, and Y Goto, and T Kondo, and S Sato, and T Takino, and T Taguchi, and I Nakao
August 1983, Nihon Gan Chiryo Gakkai shi,
Copied contents to your clipboard!